Introduction
Dementia is an age-related disorder associated with elderly population. [1] In coming decades, increased prevalence of Alzheimer's disease (AD) may pose burden on society and healthcare services, given the rapid increase in aging population in developed and developing countries. Alzheimer's disease International (ADI) estimates that there are currently 30 million people with dementia in the world and will increase to be over 100 million by 2050. [2] It is a life course illness resulting from interaction of life-style risk factors with genetic, vascular, and other risk factors to affect risk of disease. [3] Studies show that mid life obesity, metabolic syndrome, [4] insulin resistance, and type 2 Diabetes [5] as well as atherogenic/ischemic diseases [6, 7] 
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Leptin, after activation of Leptin receptors (LRp) increases N-methyl-D-aspartate (NMDA) receptor function, which in turn facilitates the induction of hippocampal long-term potentiation (LTP), partly through mitogen-activated protein kinase (MAPK). [15, 16] It is supported by the studies showing additional function of leptin on brain, in CA1 region of the hippocampus, an area integral to learning and memory. [17] At this moment, it is difficult to say that at which stage of AD leptin acts and mechanism by which high circulating concentration of leptin protect individuals from developing AD, as leptin have been shown to modulate production by reducing the activity of β secretase, a protease that cleaves amyloid precursor protein (APP) as well as clearance of amyloid β in rodent models. [18, 19] It also protects neurons against amyloid β-induced toxicity, by increasing Apolipoprotein E (APO E) dependent uptake of β amyloid into the cells.
The APO E ε4 allele is a known genetic risk factor for AD by accelerating onset. [20] It is estimated that the lifetime risk of developing AD increases to 29% for carriers with one ε4 allele and 9% for those with no ε4 allele. [21] APO E has a prominent role in the transport and metabolism of plasma cholesterol. [22] Carriers of the ε4 allele of the APO E gene (APO E ε4) have higher total and low density lipoprotein cholesterol levels than non carriers. [23] Many animal models of AD shows that high cholesterol levels increase β amyloid protein concentration and may increase APO E expression by which it increases the risk for AD, explaining the mechanism of action of APO E. [24, 25] The uptake of APO E/Aβ complexes by neurons which is allele specific, serves as a mechanism for clearing Aβ from brain interstitium. APO E 3 allele appears to be more efficient in uptake of APO E/Aβ complex as compared to APO E 4. [26] Literature shows conflicting studies regarding influence of APO E genotype on the relationship between plasma cholesterol level and dementia risk. [27] [28] [29] [30] It is well-established that the risk of AD and cognitive impairment increases in patients with pathological condition associated with high cholesterol levels, such as cardiovascular diseases. [31, 32] Cholesterol might play a role in the biosynthesis of Amyloid β. [33] However, association between cholesterol levels and dementia are inconclusive. Few studies report high cholesterol level to be a significant risk factor for dementia, others have not confirmed this finding. [27, 34] In this hospital-based cross-sectional study, with the objectives to identify the biochemical risk factors in AD, we examined the levels of serum leptin, cholesterol, low density lipoprotein (LDL-C), and high density lipoprotein (HDL-C) in the diagnosed cases of AD. Also, attempt was made to explore the association of serum leptin, total cholesterol, LDL-C, and HDL-C with cognitive decline in AD and whether the levels of these can be determined by APO E polymorphism.
Materials and Methods

Study subjects
Subjects attending Neurobehavioral clinic in the Institute of Human Behavior & Allied Sciences from 2010 to 2012 were enrolled in this cross sectional study. Each participant underwent in person interview about general health and function at the time of their entry in the study, followed by assessment if medical history, physical, and neurological examination, and a neuropsychologic battery for cognition.
Of the 200 subjects undertaken for initial screening, 88 were diagnosed as probable AD. Out of 88 subjects, 12 were excluded as their APO E polymorphism study was not done and 16 subjects' leptin level, lipid profile could not be obtained in the cross-sectional analysis (%). Thirty-nine subjects with probable AD (27 men and 12 women; mean age 66.90 years) and 42 cognitive normal individuals (22 men and 20 women; mean age 61.9 years) were involved in the cross-sectional analysis.
Patients were selected from outpatient only. All patients with history of cerebral stroke, epilepsy, head trauma, and moderate to severe depressive episodes were excluded from the study. Before enrolling subjects in the study, written informed consent was obtained. Participants who did not give consent for participation in the study were not included, in both case and control groups. Study was initiated after approval from the institutional ethics committee.
Diagnosis of AD
Dementia screening and diagnosis was done in two phases. In first phase, subjects were screened by the trained resident doctor using Mini-Mental State examination (MMSE). In second phase, screen positive subjects (MMSE <26) were subsequently assessed by a neurologist and underwent brain imaging. Diagnosis of probable AD was made according to the criteria of the National Institute of Neurological and Communicative Disorders Association-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA). [35] The diagnosis was confirmed by cerebral magnetic resonance imaging (MRI) studies, which showed a generalized atrophy with selective temp-roparietal atrophy in all the patients. NIMHANS and PGI battery of neuropsychological tests for cognition were done. All the subjects underwent clinical examination along with routine biochemical, hormonal, and radiologic examinations, including glucose, cholesterol, triglycerides, LDL-C, HDL-C, leptin, and MRI. All the cases underwent genetic testing for APO E polymorphism.
Biochemical assessment
At baseline non-fasting serum samples were obtained from patients taking all the standard precautions. The specimen was centrifuged within 30 min of sample collection to separate the serum and examined for routine biochemistry including cholesterol, LDL-C, HDL-C. All the routine biochemical parameters were measured on fully automated Biochemistry Discrete Analyser AU 480 from Beckman Coulter. Specimen for evaluation of leptin was stored at −20°C until analysis. Serum leptin was measured by using sandwich immunoassay technique, using kit from DRG, DRG Instruments Gmbh, Germany. This test was performed on enzyme-linked immunosorbant assay (ELISA) Reader Ranskan Sprint from Ranbaxy Diagnostics.
APO E genotyping
Blood samples were obtained from all patients at the time of enrolment and genomic deoxyribonucleic acid (DNA) was isolated using a modification of the salting out procedure. [36] Two non-synonymous genetic variants, rs429358 and rs7412, Annals of Indian Academy of Neurology, July-September 2015, Vol 18, Issue 3 which determine the three APO E ε isoforms were identified by sequencing 217bp exon 4 region of APO E gene. The 217bp fragment (reference sequence: GenBank AF261279) [37] was amplified using genomic DNA from each individual by forward (CCAAGGAGCTGCAGGCGGCGCA) and reverse (GCCCCGGCCTGGTACACTGCCA) primers. Amplification reaction was assembled in 25µl total volume containing 50 ng of genomic DNA using Taq polymerase (Thermo Scientific).
Following assembly, thermal cycling was performed with an initial denaturation at 94°C for 10 min followed by 35 cycles of denaturation at 94°C for 45 sec, primer annealing at 60°C for 45 sec, and primer extension at 72°C for 45 sec. After 35 cycles, a final extension was performed at 72°C for 10 min. PCR products were purified by cutting the specific product from a 1% agarose gel and isolating the product with GeneJET Gel Extraction Kit (Thermo Scientific). Purified PCR products were sequenced in 10 µl reactions with 25 ng of the sequencing primer on an ABI 3730xl DNA analyzer (Scigenom laboratory, India). Sequencing reactions were denatured for 10 sec at 9°6 C and subjected to 15 cycles at 96° C for 10 sec, 55° C for 5 sec, and 70° C for 1 min and 15 cycles at 96° C for 10 sec 70° C for 1 min. The results were analyzed using FinchTV V1.4.0 software [Geospiza, Inc].
Statistical analysis
Descriptive statistics (Mean & standard deviation) was used to describe the continuous variable under study. Independent t-test was applied to find out significant difference in average level between AD and control groups. The AD group patients were categorized in three sub-groups (mild, moderate, severe) on the basis of MMSE scores and mean of all the studied biochemical variables (serum leptin, cholesterol, triglycerides, LDL-C and HDL-C) were compared by analysis of variance (ANOVA) technique. Product-moment correlation method was applied to find out the strength and direction of relationship between MMSE score and biochemical variables among AD group. All analysis was carried out on Statistical Package of Social Sciences (SPSS) 18.0.
Results
Characteristics of study subjects
In the present case control cross-sectional study, 81 subjects, which included 39 AD and 42 control, were studied for serum levels of leptin, lipid profile, and APO E polymorphism. The average age in AD group was 66.90 ± 9.24 years, which was slightly but significantly higher than the controls (61.90 ± 7.93 years). The proportion of men in AD was more than control (27/12 & 22/20, respectively). which was not significant (P = 0.12). Table 1 describes the demographic characteristics of study population. It also describes the associated risk factors in AD and control group. AD group had more often history of hypertension (46.2%), diabetes (15.3%), hypercholesterolemia (5.1%), coronary artery disease (38.4%), and higher frequency of ε4 alleles (38.4%) compared with control group, whereas 28.6% and 9.5% subjects in control group had history of smoking and alcohol abuse, respectively, which was slightly higher than AD group. However, AD group had more uneducated subjects, i. e., cannot read and write (48.7%) than control group (40.5%). The case and control were not matched for age or education.
Allele and genotype distribution of the APO E gene in AD and control group Table 2 shows genotype distribution of APO E gene in AD as compared to controls. The frequency of ε2, ε3, and ε4 was studied in 81 subjects. Allele ε2 was present in only one patient with AD as compared to 9 out of 42 control subjects. The frequency of ε4 allele in AD (38.5%) was found to be significantly higher than in control (9.5%). ε3 allele was more frequent than ε4 allele in AD and control group.
The frequency of ε3ε3 genotype was highest in the AD group (61.5%), which was lower than control (69.0%), followed by ε3ε4 (25.6%) and ε4ε4 (10.3%), whereas ε4ε4 allele was absent in control group. In addition, ε2ε3 genotype was absent in AD, but present in 21.4% subjects in control group. Table 3 describes the descriptive statistics (mean and SD) of age, MMSE score, and biochemical variables (serum leptin, cholesterol, LDL-C, and HDL-C levels). One-way ANOVA technique was applied to compare the levels of leptin, cholesterol, triglycerides, LDL-C, and HDL-C in AD and control groups. AD group showed significantly lower levels of leptin (P = 0.00) as compared to control group. There was no significant difference in cholesterol, LDL-C, and HDL-C levels in AD and control groups, but the mean value of these variables in serum was higher in AD group as compared to control. To assess the effect of APO E polymorphism on serum leptin, cholesterol, triglycerides, LDL-C, and HDL-C levels in AD and control group, analysis was stratified by APO E genotype (no ε4 vs. at least one ε4 allele). In subjects carrying at least one ε4 allele, serum leptin levels were slightly low as compared to subjects not carrying ε4 allele [ Table 4 ]. However, this association was not significant (P = 0.07).
Serum leptin and cholesterol levels in AD
Association of leptin and lipid levels with cognitive decline in AD
To explore the association of serum leptin, total cholesterol, triglycerides, LDL-C, and HDL-C levels with cognitive decline in AD, the AD group patients were categorized in three subgroups-mild (19-24), moderate (11) (12) (13) (14) (15) (16) (17) (18) and severe (0-10), and mean of all the studied biochemical variables (serum leptin, cholesterol, triglycerides, LDL-C, and HDL-C levels) were compared by analysis of variance (ANOVA) technique [ Table 5 ]. Within subgroup no significant difference in mean value of serum leptin, cholesterol, triglycerides, LDL-C, and HDL-C levels was observed. The mean leptin level was almost comparable in all three MMSE score subgroups, whereas mean cholesterol level (155.88 ± 45.68 mg/dl)) was lowest in moderate MMSE score subgroup and highest in mild MMSE score subgroup (201 ± 44.16 mg/dl). Similarly, triglycerides, LDL-C, and HDL-C levels were highest in mild MMSE score subgroup. However, all these values were not significantly different.
Discussion
In the present study performed on small-sized sample taken from a tertiary care hospital, main findings are: 1. lower serum leptin levels were associated with a higher prevalence of AD, 2. APO E ε4 allele was raised in AD, 3. serum lipid levels were slightly but not significantly higher in AD as compared to controls, and 4. no significant association was found between low serum leptin and high serum cholesterol and AD prevalence in subjects carrying at least one APO E ε4 allele.
Our findings of reduced serum leptin levels and raised serum cholesterol and LDL-C are in agreement with other studies. [6, [38] [39] [40] Lieb et al., 2012 [6] in their landmark prospective study found association of higher baseline plasma leptin concentration with significantly lower risk of dementia and AD. During 12 year follow-up, 25% subjects developed AD in the lowest quartile of leptin as compared to 6% in highest quartile. They found correlation of circulating leptin levels with gray matter volume in brain, specifically in hippocampus. Their study suggests that higher leptin levels are associated with lower incidence of AD in non-obese individuals. Another prospective study by Holden et al., 2009 [20] performed in normal elderly, a negative correlation observed between serum leptin levels and cognitive decline, further supported our findings. They observed that elders in the high leptin group had significantly less likelihood of cognitive decline. However, Teunissen et al., 2014 [41] found no correlation between serum leptin levels and cognitive decline in AD patients, whereas Johnston et al., 2014 [42] observed low serum leptin levels in cognitively impaired AD subjects. In vitro and in vivo studies have reported that leptin impacts Aβ homeostasis and tau phosphorylation. It has also been suggested that abnormal neuronal AMPdependent kinase (AMPK) leading to modification of metabolic pathways, modulated by leptin precede amyloid plaque and neurofibrillary tangle (NFT) development. [43] An abnormal AMPK activity could lead to abnormal lipid levels and membrane composition in neurons that could affect membrane fluidity, which may lead to Aβ production. Leptin, known to regulate the AMPK activity, can reduce tau phosphorylation. Taken together; leptin can influence these pathways, prior to amyloid deposition or tau phosphorylation. Further, leptin treatment can ameliorate AD pathology by reducing the levels of Aβ 42 and phosphorylated tau. [44, 45] These biochemical and pathological changes, hallmark of AD, after leptin treatment in animal models correlate with behavioral improvements. Leptin treatment helps in Aβ clearance by reducing β-secretase activity and increasing APO E-dependent Aβ uptake [44] and decreases the hyperphosphorylation of tau in a dose dependent and synergistic manner with insulin. [46] Hence it can be suggested that leptin not only reduces AD pathology but also improves cognitive functions [45] and leptin could serve as a therapy that increases learning and memory capacity in AD patients and reduces Aβ plaques in the brain, while helping maintain adequate metabolic control. [47] Our findings, as supported by these studies suggest that the risk of developing AD is significantly lower in persons with high leptin concentration, as leptin, besides having role in energy regulation, may be neuroprotective and mitigate the progression of AD.
Our second finding is that the frequency of ε4 allele in AD (38.5%) was significantly higher than in control (9.5%). Luthra et al., 2004 [48] has reported 29.3% APO E ε4 allele frequency among AD in Indian population, which is almost similar to African American [49] (32.2%) and Japanese [49] (27.8%) population, but lower than Caucasian population [49] (36.7%). However, another study done in Indian population by Ganguly et al., 2000 [50] reported 16.07% APO E ε4 frequency among AD patients in Indian population. As seen in these studies, APO E ε4 is associated with an increased risk of AD. But, many people with APO E ε4 allele did not develop AD and also, AD developed in its absence. Heterogeneity regarding the strength of risk of AD for carriers of APO E ε4 allele in the present study may be due to small sample size, genetic drift by founder effect, and/or different prevalence rates of AD. Also, other than selection bias, factors like age, sex, smoking, hypercholesterolemia, hyperglycemia are known to modify APO E-related risk in AD. Hence, neither APO E genotyping is recommended for routine clinical diagnosis nor can be used for predictive testing. [51] However, APO E genotyping may be applied to differentiate AD and non AD dementia. It can also play a vital role in sub grouping of both AD and non-AD dementia. [52] Our third finding of slightly but not significantly raised serum lipid levels in AD as compared to controls is in agreement with longitudinal studies [53] [54] [55] showing a non-significant association between high cholesterol and HDL-C levels in midlife and the development of AD in the late life, whereas, Presecki et al., 2011 [56] reported reduced serum cholesterol, LDL-C, and HDL-C levels in patients of AD. As published data available regarding blood lipid levels and incidence of AD are contradictory, [27, 53, 57] it is not possible to conclude whether cholesterol has a protective or neurotoxic role in the development of AD. Such varied results among studies may be due to lifestyle-related modifiable risk factors like diet, alcohol, exercise, smoking, in addition to age, gender, and different methods used for lipid determination. Another possible explanation, which needs to be considered, is that most of the data available come from the short-term cohort studies, with a time interval not more than 2-6 years before the diagnosis of AD, except one study undertaken 18 years before dementia was identified. [58] The long-term follow-up studies, undertaken in mid life as a starting point show results that are opposite to those of short-term follow-up studies done in older individuals. [56] Such contradictions may be explained by the fact that total cholesterol tends to increase with age in youngor middle-aged adults, but later decreases as individuals get older. [57] Although studies show high cholesterol levels at mid life as an independent risk factor for AD, this association was not observed in late-life. [59] However, no significant association was observed between low leptin and high cholesterol and AD prevalence in subjects having APO E ε4 allele. Also, there was no significant difference between APO E ε4 allele and non APO E ε4 allele for cholesterol levels. Though there were slightly raised leptin levels in AD patients with APO E ε4 allele, but they were not significant. Similar findings have been reported by Sabbagh et al., 2006 , [60] which showed that APO E ε4 allele did not reveal any significant difference in the lipid profile except for LDL-C, whereas, Neeraj et al., 2012 [40] reported significantly high levels of serum cholesterol and LDL-C cholesterol in APO E ε3/4 genotype in patients with AD as compared to controls. Studies done by Staito et al., 2003 [61] shows that APO E ε4 isoforms have higher capacity to bind to VLDL receptor leading to raised levels of serum cholesterol and LDL-C. Hence, it can be concluded that high cholesterol serum cholesterol levels at midlife constitute a significant risk factor for AD later in life, independent to APO E ε4. [56] Lieb et al., 2009 [6] also showed no effect modification by APO E ε4 allele for interaction of APO E and leptin for the models predicting all cause dementia.
The present study is not without limitations. First, subjects taken in the study were diagnosed cases of AD taken in late life, thus it is difficult to say whether these findings are applicable to all stages of AD and in other age-groups and will be unable to address the relationship between mid-life leptin and cholesterol and cognitive decline. Further, in the present study, leptin, and lipid levels were measured in serum and not in cerebrospinal fluid and only once in each participant. However, studies show that the levels of leptin in cerebrospinal fluid (CSF) are comparable to that of serum/plasma. [6] Also, confounding factors for leptin-like waist hip ratio, body mass index, and lipids like dietary habits especially dietary fats were not examined at the baseline examination.
Conclusions
Based on the findings of present study, it can be concluded that low levels of leptin may contribute to systemic and central nervous system abnormalities leading to AD, suggesting that a leptin may be considered as possible targets for the therapeutic intervention. This may be an attractive alternative to the drugs that are currently under development. Also, APO E genotyping might improve the specificity of the differential diagnosis of dementia and in addition to serum lipids may participate as an independent risk factor for AD.
